The Scientist Staff | Jul 21, 1996 | 7 min read
OVERSATURATED: "There are more funded projects than we can absorb," says HGS's William Haseltine. Earlier this month, Human Genome Sciences Inc. (HGS), a biotech firm in Rockville, Md., and Philadelphia-based pharmaceutical giant SmithKline Beecham widened their almost three-year-old exclusive agreement to include more companies in their bioprospecting of the human genome. In research and marketing deals totaling more than $90 million over the next five years, Schering Plough Corp. of Madison